EVENTS | VIEW CALENDAR
Elsevier acquires Ariadne Genomics
AMSTERDAM, The NetherlandsóLooking to combine their offerings and "deliver better insights to research discovery and the understanding of disease mechanisms," global provider of scientific, technical, and medical information products and services Elsevier has acquired the business assets of Rockville, Md.-based Ariadne Genomics, a provider of pathway analysis tools and semantic technologies for life science researchers.
Terms and financial details of the transaction were not released. Ariadne will be integrated with Elsevier's Corporate Markets division.
"Ariadne Genomics' pathway analysis tools and semantic technologies integrate research findings from across multiple content sources providing a deeper understanding of biological pathways and disease progression," said Alexander van Boetzelaer, managing director of Elsevier Corporate Markets. "Ariadne's products improve research productivity and outcomes for life science researchers by delivering new insights for potential interventions, therapies and cures."
"Ariadne brings to Elsevier an information offering in the biology domain and a passionate and dedicated team of life science professionals," he continued. "Ariadne's team and offerings are a powerful complement to our chemistry, pre-clinical and clinical workflow solutions."
As Elsevier notes, Ariadne's flagship product, Pathway Studio, is widely used by pharmaceutical, agriculture and academic institutions to provide analyses of molecular pathways and disease progression. The integrated data mining and visualization product organizes relevant facts and relationships from large document collections of genes, proteins, cell processes and diseases. Powered by Ariadne's MedScan technology, the Pathway tools enable visualization of biological relationships spanning biomedical literature and supports the interpretation of experimental results utilizing domain-specific ontologies, taxonomies and dictionaries.
With our integration into Elsevier, we look forward to strengthening our ability to serve biological researchers in scientific communities through further development of Pathway Studio, fortified with Elsevier's content, and complementing Elsevier's leadership role across biomedical disciplines," noted Ariadne's CEO, Ilya Mazo, of the acquisition.
"As a customer of both providers, I am excited to learn that Ariadne Genomics and Elsevier have joined," said Dr. Jonathan Usuka, director of global business planning at Celgene, a multinational biopharmaceutical company. "Pathway Studio provides essential support to our immunological studies. As part of Elsevier, there is the potential to deliver even more value to our researchers."